Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.81 |
| ▸ | POLA1 | P09884 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479792 | 0.94 | KCNH2 (0.82) | KCNH2POLA1F2 | |
| SCHEMBL6706422 | 0.93 | KCNH2 (0.81) | KCNH2POLA1F2 | |
| SCHEMBL6709268 | 0.92 | KCNH2 (0.79) | KCNH2POLA1F2 | |
| SCHEMBL6662076 | 0.91 | KCNH2 (0.67) | KCNH2POLA1F2 | |
| SCHEMBL6363622 | 0.90 | KCNH2 (1.00) | KCNH2POLA1 | |
| SCHEMBL6709098 | 0.89 | KCNH2 (0.77) | KCNH2POLA1F2 | |
| Hydrochloric Acid SCHEMBL7542126 | 0.89 | KCNH2 (0.98) | KCNH2POLA1 | |
| SCHEMBL6708208 | 0.88 | KCNH2 (0.73) | KCNH2POLA1 | |
| SCHEMBL6710929 | 0.88 | KCNH2 (0.75) | KCNH2POLA1F2 | |
| SCHEMBL6491388 | 0.87 | KCNH2 (0.71) | KCNH2POLA1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | claimed |
| JP-2002539130-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | claimed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | claimed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | claimed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | claimed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | disclosed |
| US-6495683-B2 | HERPES VIRUS | PHARMACIA AND UPJOHN COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, TGFB1 | KCNH2 4238/4885POLA1 2852/4885F2 614/4885 |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IL4, ZC3HAV1 | KCNH2 813/4885POLA1 572/4885F2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.